Publications by authors named "Minjoung Park"
Purpose: Capmatinib, an oral MET kinase inhibitor, has demonstrated its efficacy against non-small cell lung cancer (NSCLC) with MET dysregulation. We investigated its clinical impact in advanced NSCLC with MET exon 14 skipping mutation (METex14) or gene amplification.
Materials And Methods: Patients who participated in the screening of a phase II study of capmatinib for advanced NSCLC were enrolled in this study.
Article Synopsis
- The study evaluated the effect of adding the anti-diabetic drug metformin to chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) to see if it improved survival rates.
- 164 patients were randomized to receive either chemotherapy alone or chemotherapy with metformin, with various tests conducted to analyze metabolic responses.
- While overall, metformin did not enhance survival in all NSCLC patients, it notably improved outcomes for patients with squamous cell carcinoma (SqCC) exhibiting high FDG uptake, suggesting a targeted approach might be beneficial.